"10.1371_journal.pone.0078797","plos one","2013-12-02T00:00:00Z","Lars Wallentin; Björn Zethelius; Lars Berglund; Kai M Eggers; Lars Lind; Bertil Lindahl; Kai C Wollert; Agneta Siegbahn","Uppsala Clinical Research Center (UCR) and Department of Medical Sciences, Uppsala University, Uppsala, Sweden; Department of Public Health/Geriatrics, Uppsala University and Medical Products Agency/Epidemiology, Uppsala, Sweden; Department of Medical Sciences, Uppsala University, Uppsala, Sweden; Division of Molecular and Translational Cardiology, Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany","Performed the experiments: LW LB BZ BL AS. Analyzed the data: LW LB BZ BL AS. Contributed reagents/materials/analysis tools: LW AS KW. Wrote the manuscript: LW LB. Provided comments and advice on the manuscript: LL KE.","Lars Wallentin and Kai C. Wollert are named as co-inventors on a patent for the use of GDF-15 for cardiovascular applications, and have a contract with Roche Diagnostics for the development of a GDF-15 assay. Björn Zethelius (BZ) is employed by the Medical Products Agency (MPA), Uppsala, Sweden and the views of the present study are his own and not necessarily any official views of the MPA. BZ has not received any benefits or financial support from any commercial sponsor. The other co-authors have no conflicts of interest. The declared patent (Assessing the risk of cardiac intervention based on GDF-15, EP application no/patent no 11150888.3 - 1223) does in no way alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed in the online guide for authors.","2013","12","Lars Wallentin","LW",8,TRUE,NA,5,5,2,TRUE,TRUE,FALSE,0,NA,FALSE
